Mice that received AAV vector injection: treated MPSIIIB mice received the AAV2.5-hNaGlu vector.
Control mice received the same volume PBS.
A control group of nude mice received the Matriderm scaffolds without cells.
All mice received the same care and housing and were evenly distributed between control and treatment groups.
Control mice received the same treatment but without defeat (Fig. 5b) and animals were tested in drug-free conditions.
Usher and heterozygous mice received the therapeutic ASO, ASO-29, or a control, non-specific ASO treatment at postnatal day five.
I/R mice received the injection of either αGC (I/R + αGC, n = 48) or vehicle (I/R + vehicle, n = 49) 30 min before reperfusion.
FVB and MT overexpression transgenic mice received the GSH synthase inhibitor buthionine sulfoximine (BSO, 30 mM) in drinking water for 2 weeks.
All the mice received the same amount of food.
After the mice received the MIF inhibitor, their blood sugar levels returned to normal, indicating that MIF is also pivotal in the progression of the disease.
Control normal mice received the control AAV vector.
